re: Ann: Omacetaxine European rights licensed... $18m up front, with another $120m in milestone payments.
Should be enough to support Chemgenex's direct marketing and sales in the US market.
Together with the evidence for the extra indication (TKI failures without T315I mutation), this is looking pretty good!
- Forums
- ASX - By Stock
- CXS
- Ann: Omacetaxine European rights licensed to Hosp
Ann: Omacetaxine European rights licensed to Hosp, page-3
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)